Silver Sulfadiazine cream is indicated for

• the topical prevention of bacterial colonization and infection in burn wounds.
• It is also used for the topical antibacterial management of contaminated or infection-prone wounds other than burns.

The exact mechanism of antibacterial action of Silver Sulfadiazine is not fully understood. After application, it causes structural damage to bacterial cell membranes, leading to distortion, enlargement of the cells, and weakening of the cell wall. This results in reduced viability of susceptible bacteria. Silver sulfadiazine dissociates, and the silver component binds to bacterial cells. It is believed that after entering the cell, silver binds to bacterial DNA (deoxyribonucleic acid), thereby inhibiting bacterial replication. Since mammalian cells contain significantly more DNA than bacterial cells, the silver-to-DNA ratio is sufficient to inhibit bacterial growth while not significantly affecting epithelial cell regeneration. The sulfadiazine component provides additional bacteriostatic activity against sensitive organisms. In adults, up to 10% of sulfadiazine may be absorbed systemically, and 60–85% of the absorbed drug is excreted in urine. In children with 13% body surface area burns, urinary sulfadiazine concentration has been reported at approximately 31.8 mg/L.

The burn wounds are cleansed, and Silver Sulfadiazine is applied over the burn wound. The burn areas should be covered with Silver Sulfadiazine at all times. The cream should be applied once to twice daily to a thickness of approximately 1/16 inches or 1.5 mm. Whenever necessary; the cream should be reapplied to any areas from which it has been removed by patient activity. If individual patient requirements make dressings necessary, they may be used. Reapplication should be ensured immediately after hydrotherapy. Treatment with Silver Sulfadiazine should be continued until satisfactory healing is occurred, or until the burn site is ready for grafting. The drug should not be withdrawn from the therapeutic regimen while there remains the possibility of infection except if a significant adverse reaction occurs.

Enzymatic debriding agents: Silver sulfadiazine may inactivate enzymatic debriding agents; therefore, concurrent use is generally not recommended.

Oral hypoglycemic agents and phenytoin: In patients with extensive burn wounds, systemic absorption of sulfadiazine may reach therapeutic levels and can enhance the effects of oral hypoglycemic agents and phenytoin. Monitoring of blood levels is advised.

Cimetidine: In patients with large-area burns, co-administration with cimetidine has been associated with an increased risk of leukopenia.

Silver sulfadiazine is contraindicated in patients with known hypersensitivity to the drug or any of its components. It should not be used in pregnant women near term, premature infants, or newborns within the first two months of life.

Reported adverse effects include transient leukopenia (most common), skin necrosis, erythema multiforme, skin discoloration, burning sensation, rash, and interstitial nephritis (rare).

Pregnancy Category B. Silver sulfadiazine should be used during pregnancy only if clearly necessary, especially in women near term. It is unknown whether the drug is excreted in human milk. A decision should be made whether to discontinue breastfeeding or discontinue the drug, considering the importance of therapy to the mother. Pediatric use: Safety and effectiveness in pediatric patients have not been established.

General: In patients with impaired hepatic or renal function, reduced drug elimination may lead to accumulation; therefore, therapy should be reassessed based on clinical benefit. When used with topical proteolytic enzymes, silver may inactivate these agents, reducing their effectiveness.

Laboratory Tests: In extensive burn cases, serum sulfonamide levels may reach therapeutic ranges (8–12 mg%). Monitoring of serum levels may be necessary. Renal function should be regularly assessed, and urine should be checked for sulfa crystal formation.

Topical antibacterial preparations

Store below 30°C in a dry place, protected from light and moisture. Keep out of reach of children.